Cascade Technologies announced that its wholly-owned subsidiary, Spectral Molecular Imaging (SMI) has completed the development of its SkinSpect instrument. The SkinSpect is suitable for detecting melanoma in advance, using Cascade Technologies’ proprietary hyperspectral imaging technology. The SkinSpect was recently introduced at the corporate headquarters of SMI in Beverly Hills.
SMI’s President, Dr. Erik Lindsley stated that the SkinSpect uses advanced developments in polarization-gated detection, autofluorescence measurement, and hyperspectral imaging. Lindsley added that the software-controlling image handling and acquisition is operated using a touch-screen interface. This feature allows convenient patient and data monitoring, internet-based tele-consults and data transfer, as well as image archiving and analysis. He continued that the SkinSpect’s design is favorable and compliant to electronic medical record tracking and generation.
SMI’s Chairman and CEO, Dr. Daniel Farkas noted that the SkinSpect instrument is ideal for capturing high-resolution image data from skin lesions beneath and on the skin, in a non-invasive way. He added that the image capture offers a speed that minimizes motion artifacts.
Source: http://www.spectralmi.com/